A Study of a Weight Loss Intervention in People With Endometrial Cancer

This study tests whether adding a weight-loss medication (tirzepatide or semaglutide — similar to Ozempic/Mounjaro) helps people with endometrial (uterine) cancer who are overweight or obese and are already receiving chemotherapy after surgery. **You may be eligible if...** - You are 18 or older with newly diagnosed stage I–III endometrial cancer - You have already had surgery to remove the uterus and ovaries with no cancer left behind - You are about to start or recently started chemotherapy (within 3 weeks of first cycle) - You are obese (BMI ≥ 30), overweight with a related health condition (BMI ≥ 27), or have Type 2 diabetes (BMI ≥ 25) - Your insurance covers or you can pay out-of-pocket for tirzepatide/semaglutide **You may NOT be eligible if...** - You have Type 1 diabetes - You have a personal or family history of a specific thyroid cancer (medullary thyroid carcinoma) linked to a genetic syndrome - You have a history of pancreatitis, gastroparesis, or a prior weight-loss surgery/device - You are currently pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.